id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-292892-6gwnhkn4	Liu, Bingwen	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?	2020-04-10		.txt	text/plain	2708	155	36	title: Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Although clinical data of IL-6 blockade in virus 162 infection-related CRS are unavailable, animal studies of SARS-CoV have 163 demonstrated that inhibiting nuclear factor kappa-B (NF-κB), a key transcription factor 164 of IL-6, or infecting animals with SARS-CoV lacking the coronavirus envelope (E) 165 protein, a strong stimulus to NF-κB signaling, increased animal survival, with reduced 166 IL-6 levels [38] . T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients	./cache/cord-292892-6gwnhkn4.txt	./txt/cord-292892-6gwnhkn4.txt